Skip to main content
SpringerLink
Log in

Use of Economic Evaluation in Decision Making

Evidence and Recommendations for Improvement

  • Current Opinion
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Information about the value for money of a medicine as derived from an economic evaluation can be used for decision-making purposes by policy makers, healthcare payers, healthcare professionals and pharmaceutical companies. This article illustrates the use of economic evaluation by decision makers and formulates a number of recommendations to enhance the use of such evaluations for decision-making purposes.

Over the last decades, there has been a substantial increase in the number of economic evaluations assessing the value for money of medicines. Economic evaluation is used by policy makers and healthcare payers to inform medicine pricing/reimbursement decisions in more and more countries. It is a suitable tool to evaluate medicines and to present information about their value for money to decision makers in a familiar format. In order to fully exploit the use of economic evaluation for decision-making purposes, researchers need to take care to conduct such economic evaluations according to methodologically sound principles. Additionally, researchers need to take into account the decision-making context. They need to identify the various objectives that decision makers pursue and discuss how decision makers can use study findings to attain these objectives.

These issues require further attention from researchers, policy makers, healthcare payers, healthcare professionals and pharmaceutical companies with a view to optimizing the use of economic evaluation in decision making.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Grootendorst P, Pierard E, Shim M. Life-expectancy gains from pharmaceutical drugs: a critical appraisal of the literature. Expert Rev Pharmacoecon Outcomes Res 2009; 9(4): 353–64

    Article  PubMed  Google Scholar 

  2. Perleth M, Jakubowski E, Busse R. What is 'best practice' in health care? State of the art and perspectives in improving the effectiveness and efficiency of the European health care systems. Health Pol 2001 Jun; 56(3): 235–50

    Article  CAS  Google Scholar 

  3. Drummond M, Sculpher MJ, Torrance GW, et al. Methods for the economic evaluation of health care programmes. 3rd ed. Oxford: Oxford University Press, 2005

  4. Drummond M, Brown R, Fendrick AM, et al. Use of pharmacoeconomics information: report of the ISPOR Task Force on use of pharmacoeconomic/health economic information in health-care decision making. Value Health 2003 Jul; 6(4): 407–16

    Article  PubMed  Google Scholar 

  5. entre for the Evaluation of Value and Risk in Health. The Tufts Cost-Effectiveness Analysis Registry [online]. Available from URL: https://research.tufts-nemc.org/cear/default.aspx [Accessed 2010 Apr 16]

  6. McMaster University. Health Economic Evaluations Database [online]. Available from URL: http://library.mcmaster.ca/articles/health-economic-evaluations-database [Accessed 2010 Apr 16]

  7. Centre for Reviews and Dissemination. National Health Service Economic Evaluation Database [online]. Available from URL: http://www.york.ac.uk/inst/crd/ [Accessed 2010 Apr 16]

  8. Pharmaceutical Benefits Advisory Committee [online]. Available from URL: http://www.health.gov.au/internet/main/publishing.nsf/Content/Pharmaceutical+Benefits+Advisory+Committee-1 [Accessed 2010 Jul 27]

  9. Medicine Reimbursement Committee [online]. Available from URL: http://www.riziv.fgov.be/drug/nl/drugs/decisions_report/report_crm_cgt/index.htm [Accessed 2010 Jul 27]

  10. National Institute for Health and Clinical Excellence [online]. Available from URL: http://www.nice.org.uk [Accessed 2010 Jul 27]

  11. High Health Authority [online]. Available from URL: http://www.has-sante.fr/portail/jcms/j_5/accueil [Accessed 2010 Jul 27]

  12. Institute for Quality and Efficiency in Health Care [online]. Available from URL: http://www.iqwig.de [Accessed 2010 Jul 27]

  13. Health Care Insurance Board [online]. Available from URL: http://www.cvz.nl [Accessed 2010 Jul 27]

  14. Pharmaceutical Management Agency [online]. Available from URL: http://www.pharmac.govt.nz [Accessed 2010 Jul 27]

  15. Scottish Medicines Consortium [online]. Available from URL: http://www.scottishmedicines.org.uk/smc/CCC_FirstPage.jsp [Accessed 2010 Jul 27]

  16. Dental and Pharmaceutical Benefits Agency [online]. Available from URL: http://www.tlv.se/in-english [Accessed 2010 Jul 27]

  17. Center for Drug Evaluation, Taiwan [online]. Available from URL: http://www.cde.org.tw/eng/default.html [Accessed 2010 Jul 27]

  18. Simoens S. Health economic assessment: a methodological primer. Int J Environ Res Public Health 2009; 6(12): 2950–66

    Article  PubMed  Google Scholar 

  19. National Centre for Pharmacoeconomics. A review of the cost-effectiveness of sunitinib (Sutent®) under the High Tech Drug Scheme in Ireland [online]. Available from URL: http://www.ncpe.ie/u_docs/doc_129.pdf [Accessed 2010 Jul 27]

  20. Weinstein MC, Zeckhauser R. Critical ratios and efficient allocation. J Public Econ 1973; 2: 147–57

    Article  Google Scholar 

  21. George B, Harris A, Mitchell A. Cost-effectiveness analysis and the consistency of decision making: evidence from pharmaceutical reimbursement in Australia (1991 to 1996). Pharmacoeconomics 2001; 19: 1103–9

    Article  PubMed  CAS  Google Scholar 

  22. Laupacis A, Feeny D, Detsky AS, et al. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ 1992; 146: 473–81

    PubMed  CAS  Google Scholar 

  23. Raftery J. Review of NICE's recommendations, 1999–2005. BMJ 2006; 332: 1266–8

    Article  PubMed  Google Scholar 

  24. Rawlins MD, Culyer AJ. National Institute for Clinical Excellence and its value judgments. BMJ 2004; 329: 224–7

    Article  PubMed  Google Scholar 

  25. Health Care Insurance Board. Richtlijnen voor farmacoeconomisch onderzoek [guidelines for pharmaco-economic research]. Amstelveen: Health Care Insurance Board, 1999

    Google Scholar 

  26. Webb D. Early assessment of cost-effectiveness. Congress of the European Association for Clinical Pharmacology and Therapeutics; 2009 Jul 12–15; Edinburgh

  27. Grosse SD. Assessing cost-effectiveness in healthcare: history of the $50000 per QALY threshold. Expert Rev Pharmacoecon Outcomes Res 2008; 8: 165–78

    Article  PubMed  Google Scholar 

  28. National Institute for Health and Clinical Excellence. The guidelines manual 2009. London: National Institute for Health and Clinical Excellence [online]. Available from URL: http://www.nice.org.uk/aboutnice/howwework/developingniceclinicalguidelines/clinicalguidelinedevelopmentmethods/GuidelinesManual2009.jsp [Accessed 2010 Jul 28]

  29. Cleemput I, Neyt M, Thiry N, et al. Thresholds for cost-effectiveness in health care. Brussels: Belgian Health Care Knowledge Centre, 2008

    Google Scholar 

  30. Simoens S. How to assess the value of medicines? Frontiers Pharmacoeconomics Health Outcomes. In press

  31. Drummond M, Evans B, LeLorier J, et al. Evidence and values: requirements for public reimbursement of drugs for rare diseases. A case study in oncology. Can J Clin Pharmacol 2009; 16(2): e273–81

    PubMed  Google Scholar 

  32. Simoens S. Health economics of market access for biopharmaceuticals and biosimilars. J Med Econ 2009 Sep; 12(3): 211–8

    Article  PubMed  Google Scholar 

  33. Simoens S, Laekeman G. Applying health technology assessment to pharmaceutical care: pitfalls and future directions. Pharm World Sci 2005 Apr; 27(2): 73–5

    Article  PubMed  Google Scholar 

  34. Galani C, Rutten FF. Self-reported healthcare decision-makers' attitudes towards economic evaluations of medical technologies. Curr Med Res Opin. Epub 2008 Sep 29

  35. Traulsen JM, Klinke BO. Using health technology assessment to put pharmaceutical care on the political agenda. Pharm World Sci 2004 Apr; 26(2): 61–3

    Article  PubMed  Google Scholar 

  36. Hoffmann C, Graf von der Schulenburg JM. The influence of economic evaluation studies on decision making: a European survey. The EUROMET Group. Health Pol 2000 Jul; 52(3): 179–92

    Article  CAS  Google Scholar 

  37. Neumann PJ, Fang C, Cohen J. 30 years of pharmaceutical cost-utility analyses: growth, diversity, and methodological improvement. Pharmacoeconomics 2009; 27(10): 861–72

    Article  PubMed  Google Scholar 

  38. Neumann PJ, Greenberg D, Olchanski NV, et al. Growth and quality of the cost-utility literature, 1976–2001. Value Health 2005 Jan–Feb; 8(1): 3–9

    Article  PubMed  Google Scholar 

  39. Eddama O, Coast J. A systematic review of the use of economic evaluation in local decision-making. Health Pol 2008 May; 86(2–3): 129–41

    Article  Google Scholar 

  40. Drummond M, Barbieri M, Cook J, et al. Transferability of economic evaluations across jurisdictions: ISPOR Good Research Practices Task Force Report. Value Health 2009 Jun; 12(4): 409–18

    Article  PubMed  Google Scholar 

  41. Stoykova B, Drummond M, Barbieri M, et al. The lag between effectiveness and cost-effectiveness evidence of new drugs: implications for decision-making in health care. Eur J Health Econ 2003 Nov; 4(4): 313–8

    Article  PubMed  Google Scholar 

  42. Tilson L, Barry M. Recent developments in Pharmacoeconomic evaluation in Ireland. Expert Rev Pharmacoecon Outcomes Res 2010; 10(3): 221–4

    Article  PubMed  Google Scholar 

  43. Vinck I, Neyt M, Thiry N, et al. A procedure for the assessment of new medical devices. KCE reports 44A ed. Brussels: Belgian Health Care Knowledge Centre, 2006

    Google Scholar 

  44. Tunis SR, Pearson SD. Coverage options for promising technologies: Medicare's ‘coverage with evidence development’. Health Aff 2006; 25: 1218–30

    Article  Google Scholar 

  45. Cook JP, Vernon JA, Manning R. Pharmaceutical risk-sharing agreements. Pharmacoeconomics 2008; 26: 551–6

    Article  PubMed  Google Scholar 

  46. Bell CM, Urbach DR, Ray JG, et al. Bias in published cost effectiveness studies: systematic review. BMJ 2006 Mar; 332(7543): 699–703

    Article  PubMed  Google Scholar 

  47. Miners AH, Garau M, Fidan D, et al. Comparing estimates of cost effectiveness submitted to the National Institute for Clinical Excellence (NICE) by different organisations: retrospective study. BMJ 2005 Jan; 330(7482): 65

    Article  PubMed  CAS  Google Scholar 

  48. Cleemput I, Van WP, Vrijens F, et al. Guidelines for pharmaco-economic evaluation in Belgium. Brussels: Belgian Health Care Knowledge Centre, 2008

  49. GRADE Working Group [online]. Available from URL: http://www.gradeworkinggroup.org/ [Accessed 2010 Jul 27]

  50. SIGN [online]. Available from URL: http://www.sign.ac.uk/[Accessed 2010 Jul 27]

  51. Thurston SJ, Craig D, Wilson P, et al. Increasing decision-makers' access to economic evaluations: alternative methods of communicating the information. Int J Technol Assess Health Care 2008; 24(2): 151–7

    Article  PubMed  Google Scholar 

  52. Innvaer S, Vist G, Trommald M, et al. Health policy-makers' perceptions of their use of evidence: a systematic review. J Health Serv Res Policy 2002 Oct; 7(4): 239–44

    Article  PubMed  Google Scholar 

  53. Drummond M, Jonsson B. Moving beyond the drug budget silo mentality in Europe. Value Health 2003 Jul; 6 Suppl. 1: S74–7

    Article  PubMed  Google Scholar 

  54. Mitton CR, Donaldson C. Setting priorities and allocating resources in health regions: lessons from a project evaluating program budgeting and marginal analysis (PBMA). Health Policy 2003; 64: 335–48

    Article  PubMed  Google Scholar 

  55. Wettermark B, Godman B, Andersson K, et al. Recent national and regional drug reforms in Sweden: implications for pharmaceutical companies in Europe. Pharmacoeconomics 2008; 26(7): 537–50

    Article  PubMed  Google Scholar 

  56. Williams I, McIver S, Moore D, et al. The use of economic evaluations in NHS decision-making: a review and empirical investigation. Health Technol Assess 2008 Apr; 12(7): iii, ix-x, 1-175

    CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Research Centre for Pharmaceutical Care and Pharmaco-economics, Katholieke Universiteit Leuven, Onderwijs en Navorsing 2 Herestraat 49, PO Box 521, 3000, Leuven, Belgium

    Steven Simoens

Authors
  1. Steven Simoens
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Steven Simoens.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Simoens, S. Use of Economic Evaluation in Decision Making. Drugs 70, 1917–1926 (2010). https://doi.org/10.2165/11538120-000000000-00000

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/11538120-000000000-00000

Keywords

Search

Navigation